HFE polymorphisms affect cellular glutamate regulation

Neurobiology of Aging

Volumn 32, Issue 6, 2011, Pages 1114-1123

  Mitchell, Ryan M ^a   Lee, Sang Y ^a   Simmons, Zachary ^a   Connor, James R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Glutamate; HFE; Iron

Indexed keywords

ASPARTIC ACID; CALCIUM; GLUTAMIC ACID; HISTIDINE; IRON;

AMINO ACID TRANSPORT; ARTICLE; ASTROCYTOMA CELL; CALCIUM CELL LEVEL; CELL LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DNA POLYMORPHISM; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HFE GENE; HUMAN; HUMAN CELL; IRON BALANCE; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN VARIANT; REGULATORY MECHANISM;

ANALYSIS OF VARIANCE; CALCIUM; CELL LINE, TUMOR; DEFEROXAMINE; ENZYME INHIBITORS; FERRIC COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; GLUTAMINASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTRACELLULAR FLUID; IRON; MEMBRANE PROTEINS; MINOCYCLINE; NEUROBLASTOMA; POLYMORPHISM, GENETIC; QUATERNARY AMMONIUM COMPOUNDS; SIDEROPHORES; SODIUM; TACRINE; TRANSFECTION; TRITIUM; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 79955957835     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.05.016     Document Type: Article

References (42)

1. Buchanan D.D., Silburn P.A., Chalk J.B., Le Couteur D.G., Mellick G.D. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci. Lett. 2002, 327(2):91-94.
2. Chitambar C.R., Kotamraju S., Wereley J.P. Expression of the hemochromatosis gene modulates the cytotoxicity of doxorubicin in breast cancer cells. Int. J. Cancer 2006, 119(9):2200-2204.
3. Connor J.R., Lee S.Y. HFE mutations and Alzheimer's disease. J. Alzheimers Dis. 2006, 10(2-3):267-276.
4. Daikhin Y., Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. J. Nutr. 2000, 130(4S Suppl.):1026S-1031S.
5. Dekker M.C., Giesbergen P.C., Njajou O.T., van Swieten J.C., Hofman A., Breteler M.M., van Duijn C.M. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci. Lett. 2003, 348(2):117-119.
6. Ellervik C., Tybjaerg-Hansen A., Appleyard M., Sillesen H., Boysen G., Nordestgaard B.G. Hereditary hemochromatosis genotypes and risk of ischemic stroke. Neurology 2007, 68(13):1025-1031.
7. Feder J.N., Penny D.M., Irrinki A., Lee V.K., Lebron J.A., Watson N., Tsuchihashi Z., Sigal E., Bjorkman P.J., Schatzman R.C. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. USA 1998, 95(4):1472-1477.
8. Ghijsen W.E., Leenders A.G., Lopes da Silva F.H. Regulation of vesicle traffic and neurotransmitter release in isolated nerve terminals. Neurochem. Res. 2003, 28(10):1443-1452.
9. Goodall E.F., Greenway M.J., van Marion I., Carroll C.B., Hardiman O., Morrison K.E. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 2005, 65(6):934-937.
10. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6(12):1045-1053.
11. Grenier D., Huot M.P., Mayrand D. Iron-chelating activity of tetracyclines and its impact on the susceptibility of Actinobacillus actinomycetemcomitans to these antibiotics. Antimicrob. Agents Chemother. 2000, 44(3):763-766.
12. Guerreiro R.J., Bras J.M., Santana I., Januario C., Santiago B., Morgadinho A.S., Ribeiro M.H., Hardy J., Singleton A., Oliveira C. Association of HFE common mutations with Parkinson's disease. Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 2006, 6:24.
13. Hajnoczky G., Csordas G., Das S., Garcia-Perez C., Saotome M., Sinha Roy S., Yi M. Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial Ca2+ uptake in apoptosis. Cell Calc. 2006, 40(5-6):553-560.
14. Hazell A.S. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 2007, 50(7-8):941-953.
15. Ill A.M., Mitchell T.R., Neely E.B., Connor J.R. Metabolic analysis of mouse brains that have compromised iron storage. Metab. Brain Dis. 2006, 21(2-3):77-87.
16. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nat. Neurosci. 2002, 5 Suppl.:1039-1042.
17. Kraus R.L., Pasieczny R., Lariosa-Willingham K., Turner M.S., Jiang A., Trauger J.W. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem. 2005, 94(3):819-827.
18. Kriz J., Nguyen M.D., Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002, 10(3):268-278.
19. Lawless M.W., Mankan A.K., White M., O'Dwyer M.J., Norris S. Expression of hereditary hemochromatosis C282Y HFE protein in HEK293 cells activates specific endoplasmic reticulum stress responses. BMC Cell. Biol. 2007, 8:30.
20. Lawless M.W., White M., Mankan A.K., O'Dwyer M.J., Norris S. Elevated MCP-1 serum levels are associated with the H63D mutation and not the C282Y mutation in hereditary hemochromatosis. Tissue Antigens 2007, 70(4):294-300.
21. Lee S.Y., Patton S.M., Henderson R.J., Connor J.R. Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. FASEB J. 2007, 21(2):564-576.
22. Levy J.E., Montross L.K., Cohen D.E., Fleming M.D., Andrews N.C. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999, 94(1):9-11.
23. Mansson R., Hansson M.J., Morota S., Uchino H., Ekdahl C.T., Elmer E. Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol. Dis. 2007, 25(1):198-205.
24. McGahan M.C., Harned J., Mukunnemkeril M., Goralska M., Fleisher L., Ferrell J.B. Iron alters glutamate secretion by regulating cytosolic aconitase activity. Am. J. Physiol. Cell. Physiol. 2005, 288(5):C1117-C1124.
25. Moechars D., Weston M.C., Leo S., Callaerts-Vegh Z., Goris I., Daneels G., Buist A., Cik M., van der Spek P., Kass S., Meert T., D'Hooge R., Rosenmund C., Hampson R.M. Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain. J. Neurosci. 2006, 26(46):12055-12066.
26. Pereira C., Ferreira C., Carvalho C., Oliveira C. Contribution of plasma membrane and endoplasmic reticulum Ca(2+)-ATPases to the synaptosomal [Ca2+]i increase during oxidative stress. Brain Res. 1996, 713(1-2):269-277.
27. Rego A.C., Santos M.S., Oliveira C.R. Oxidative stress, hypoxia, and ischemia-like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. J. Neurochem. 1996, 66(6):2506-2516.
28. Restagno G., Lombardo F., Ghiglione P., Calvo A., Cocco E., Sbaiz L., Mutani R., Chio A. HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. J. Neurol. Neurosurg. Psychiatry 2007, 78(3):327.
29. Robb S.J., Robb-Gaspers L.D., Scaduto R.C., Thomas A.P., Connor J.R. Influence of calcium and iron on cell death and mitochondrial function in oxidatively stressed astrocytes. J. Neurosci. Res. 1999, 55(6):674-686.
30. Robson K.J., Lehmann D.J., Wimhurst V.L., Livesey K.J., Combrinck M., Merryweather-Clarke A.T., Warden D.R., Smith A.D. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J. Med. Genet. 2004, 41(4):261-265.
31. Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA 1993, 90(14):6591-6595.
32. Sala G., Beretta S., Ceresa C., Mattavelli L., Zoia C., Tremolizzo L., Ferri A., Carri M.T., Ferrarese C. Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu, Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis. Neurochem. Int. 2005, 46(3):227-234.
33. Sutedja N.A., Sinke R.J., Van Vught P.W., Van der Linden M.W., Wokke J.H., Van Duijn C.M., Njajou O.T., Van der Schouw Y.T., Veldink J.H., Van den Berg L.H. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch. Neurol. 2007, 64(1):63-67.
34. Suzuki Y.J., Ford G.D. Inhibition of Ca(2+)-ATPase of vascular smooth muscle sarcoplasmic reticulum by reactive oxygen intermediates. Am. J. Physiol. 1991, 261(2 Pt 2):H568-H574.
35. Takamori S., Rhee J.S., Rosenmund C., Jahn R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 2000, 407(6801):189-194.
36. Trotti D., Rolfs A., Danbolt N.C., Brown R.H., Hediger M.A. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 1999, 2(5):427-433.
37. Van Damme P.u., Dewil M., Robberecht W., Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener. Dis. 2005, 2(3-4):147-159.
38. Van Den Bosch L., Tilkin P., Lemmens G., Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002, 13(8):1067-1070.
39. Wang X.S., Lee S., Simmons Z., Boyer P., Scott K., Liu W., Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J. Neurol. Sci. 2004, 227(1):27-33.
40. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA 1999, 96(23):13496-13500.
41. Zhang W., Narayanan M., Friedlander R.M. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 2003, 53(2):267-270.
42. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417(6884):74-78.